|Bid||98.72 x 1200|
|Ask||98.36 x 900|
|Day's Range||92.97 - 99.69|
|52 Week Range||72.97 - 109.42|
|Beta (3Y Monthly)||0.60|
|PE Ratio (TTM)||13.81|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If the Offer is fully subscribed, the number of shares to be purchased in the Offer represents approximately 6.3% to 7.3% of Taro’s currently issued and outstanding shares depending on the purchase price payable for those shares pursuant to the Offer. The Offer will expire at 5:00 p.m., New York City time, on Monday, December 16, 2019, unless extended by Taro. Tenders of shares must be made prior to the expiration of the Offer and may be withdrawn at any time prior to the expiration of the Offer.
Taro Pharmaceutical Industries Ltd. announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2019, filed with the Securities and Exchange Commission , is available within the Investor Relations section of Taro’s website at www.taro.com.
NEW YORK, NY / ACCESSWIRE / May 23, 2019 / Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on May 23, 2019 at ...
Taro Pharmaceutical Industries Ltd. announced today that it plans to release its financial results for the quarter ended December 31, 2018, after the close of market on Wednesday, February 6, 2019.
Taro Pharmaceutical Industries Ltd. announced today that it has completed its $250 million share repurchase program. The company bought back 2,493,378 of its ordinary shares in open market transactions at an average price of $100.28 per share.
LAVAL, QC, Dec. 17, 2018 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Pliaglis® following its mandated six-month review process, in line with the target action date under the Prescription Drug User Fee Act (PDUFA). In 2017, Taro Pharmaceuticals Inc. (Taro), our licensee for Pliaglis in the U.S. market, completed the study to support the removal of the Pliaglis "Not for Home Use" label restriction and filed the FDA submission with the proposed label change on June 8, 2018.